-
A case-control study of antimicrobials and glioma risk
Time of Update: 2023-01-06
of the Department of Neurology at the University Hospital Regensburg, Germany, conducted a case-control study based on a large and validated database to explore the relationship between antimicrobial use and glioma risk.
-
Rare target detection of lung cancer, so that every "rare" is "seen"
Time of Update: 2023-01-06
At the 5th China International Import Expo (hereinafter referred to as the "Expo"), Roche Diagnostics and Roche Pharmaceutical, together with seven leading domestic genetic testing medical technology
-
Frameless robot-guided stereotactic biopsy for the diagnosis of diffuse endogenous pontine glioma in children
Time of Update: 2023-01-06
[Epub ahead of print] 】 Research background Diffuse endogenous pontine glioma (DIPG) in children has a deep location, special location, high surgical risk, and is prone to serious complications after surgery, with an average survival of less than 1 year.
-
Frameless robot-guided stereotactic biopsy for the diagnosis of diffuse endogenous pontine glioma in children
Time of Update: 2023-01-06
[Epub ahead of print] 】 Research background Diffuse endogenous pontine glioma (DIPG) in children has a deep location, special location, high surgical risk, and is prone to serious complications after surgery, with an average survival of less than 1 year.
-
Iron death in gliomas can induce immunotherapy resistance
Time of Update: 2023-01-06
Professor Wu Anhua of the Department of Neurosurgery of the First Affiliated Hospital of China Medical University and other studies have determined that ferrozosis is the most common PCD among gliomas, and is highly correlated with malignant progression, low survival rate and immunotherapy resistance of gliomas.
-
Ask the big coffee, life is far-reaching| Professor Bi Feng: Mechanics is practiced, perseverance: the road of targeted therapy exploration for colorectal cancer
Time of Update: 2023-01-06
In recent years, various new drugs/therapies around colorectal cancer treatment have emerged one after another, especially targeted therapy has now become the "mainstay" in the field of colorectal can
-
FLOWERS STUDY: EXPLORING COMBINATION STRATEGIES FOR PRIMARY RESISTANCE TO EGFR TKI
Time of Update: 2023-01-06
In response to this practical clinical problem, the team of Professor Yang Genji of Guangdong Provincial People's Hospital designed a phase II prospective, dual-cohort, randomized multi-center FLOWERS clinical trial to evaluate the efficacy and safety of osimertinib ± sevotinib for first-line treatment in patients with primary MET amplification/overexpression, EGFR mutation-positive, and advanced non-small cell lung cancer (NSCLC。 THE FLOWERS STUDY DESIGN WAS RECENTLY PUBLISHED IN THE JOURNAL LUNG CANCER.
-
2022 CSCO |Professor Jiang Zefei: CSCO Academic Week kicked off in Beijing, focusing on cutting-edge progress and sharing academic feasts
Time of Update: 2023-01-06
Yimaitong: The academic week of this year's CSCO Annual Conference was held in the mode of "online + offline", which not only brought together the progress of multi-tumor diagnosis and treatment, but also focused on innovative tumor drugs, artificial intelligence, patient education and other fields, and discussed the clinical frontier of tumor in all aspects and dimensions.
-
Precise innovation, wisdom and humanities Bearing the 25th anniversary of ups and downs, the 2022 CSCO Annual Meeting was grandly opened in Beijing!
Time of Update: 2023-01-06
The 25th National Congress of Clinical Oncology and the 2022 Chinese Society of Clinical Oncology Annual Conference officially kicked off in Beijing today, and the conference was held in the form of "
-
Focusing on Exploration, Exploration and Innovation China's Innovation, New Options for Anti-HER2 Treatment - The 2022 CSCO Annual Meeting Septin ® Satellite Meeting was successfully held
Time of Update: 2023-01-06
Professor Wang Shusen briefly summarized the first chapter: Professor Chen Wenyan started from the treatment strategy of advanced HER2-positive breast cancer, from the arrangement of first-line, second-line and posterior drugs and the latest research trends of clinical drugs, macromolecular monoclonal antibody H drugs are the cornerstone of anti-HER2 treatment, while small molecule TKI and the latest ADC drugs are also leading the way, which is worth looking forward to!
-
2022 CSCO Professor Liang Jun talked about the development process and future prospects of systemic treatment of liver cancer
Time of Update: 2023-01-06
Professor Liang Jun: Systematic treatment is an indispensable part of multidisciplinary diagnosis and treatment of liver cancer, and the survival of liver cancer patients in the early chemotherapy era is generally poor, and later the application of tyrosine kinase inhibitors (TKI) such as sorafenib, lenvatinib and donafenib has opened up a new era for the systematic treatment of liver cancer.
-
International Frontier, Normative Leading HCC International Frontier and Norm Summit Forum was successfully held
Time of Update: 2023-01-06
Chapter 2: Normative Guidance Professor Cui Zilin of Tianjin First Central Hospital reviewed the initial exploration of atezolizumab and bevacizumab in the theme report "Past, present and future of systematic treatment of advanced liver cancer", sorted out the course of atezolizumab + bevacizumab (T+A protocol) in the collaborative fight against HCC, and shared a series of exploratory research new progress, describing the future of atezolizumab + bevacizumab, including MO42541, TALENTACE, IMbrave 050, ABC-HCC and TALENTOP studies, among others.
-
CSCO's first live broadcast room | upper gastrointestinal system tumors ushered in an immunotherapy feast
Time of Update: 2023-01-06
Figure 1: OS, PFS, ORR, and duration of response (DOR) in PD-L1 CPS≥5 and all randomized populations in nivolumab plus chemotherapy versus chemotherapy Immunotherapy is also gaining momentum in the field of esophageal cancer, and a number of advanced first-line phase III clinical studies have been published, consolidating the position of immunotherapy combined with chemotherapy in the first-line treatment of esophageal cancer.
-
Olaparib in combination with temozolomide for glioma
Time of Update: 2023-01-06
[Epub ahead of print] 】 Research background Glioma is a common intracranial malignancy that can be avoided after treatment.
In summary, this study analyzes the efficacy and complications of olaparib + TMZ combination in glioma patients, laying a foundation for further clinical trials.
-
Ask the big coffee, life is far-reaching| Professor Bi Feng: Mechanics is practiced, perseverance: the road of targeted therapy exploration for colorectal cancer
Time of Update: 2023-01-06
In recent years, various new drugs/therapies around colorectal cancer treatment have emerged one after another, especially targeted therapy has now become the "mainstay" in the field of colorectal can
-
FLOWERS STUDY: EXPLORING COMBINATION STRATEGIES FOR PRIMARY RESISTANCE TO EGFR TKI
Time of Update: 2023-01-06
In response to this practical clinical problem, the team of Professor Yang Genji of Guangdong Provincial People's Hospital designed a phase II prospective, dual-cohort, randomized multi-center FLOWERS clinical trial to evaluate the efficacy and safety of osimertinib ± sevotinib for first-line treatment in patients with primary MET amplification/overexpression, EGFR mutation-positive, and advanced non-small cell lung cancer (NSCLC。 THE FLOWERS STUDY DESIGN WAS RECENTLY PUBLISHED IN THE JOURNAL LUNG CANCER.
-
When discussing the "three perfections" of tumor immunotherapy in the upper gastrointestinal system
Time of Update: 2023-01-06
Nivolumab in combination with chemotherapy continued the excellent performance in the CheckMate-649 study, with OS benefit observed in all populations; At the same time, the OS benefit was not limited by PD-L1 expression in all randomized patients3 In addition, postoperative adjuvant therapy for esophageal cancer has lacked large-scale clinical research data, and the effect of postoperative traditional chemotherapy is not good.
-
Rare target detection of lung cancer, so that every "rare" is "seen"
Time of Update: 2023-01-06
At the 5th China International Import Expo (hereinafter referred to as the "Expo"), Roche Diagnostics and Roche Pharmaceutical, together with seven leading domestic genetic testing medical technology
-
Wang Hai's team of the National Nano Center has made a new breakthrough in tumor nanovaccines
Time of Update: 2023-01-05
On October 11, 2022, the research team of Wang Hai of the National Center for Nanoscience of the Chinese Academy of Sciences published a report in the journal Advanced Materials entitled: Research paper on Direct Presentation of Tumor-Associated Antigens to Induce Adaptive Immunity by Personalized Dendritic Cell-Mimicking Nanovaccines.
-
Shine! Axitinib combined with immune second-line treatment for advanced kidney cancer with PFS for up to 29 months
Time of Update: 2023-01-05
In this case, the patient with clear cell carcinoma of the left kidney recurred after surgery and multiple metastases to both lungs, thoracolumbar spine (IMDC is high-risk), how to develop an individualized and precise comprehensive treatment strategy for him in clinical practice?IMDC high-risk groups, how to choose first-line treatment?Studies have shown that anti-angiogenic therapy can normalize the abnormal tumor vascular system to increase the infiltration of immune effector cells, that is, the immunosuppressed tumor microenvironment into an immune-enhanced tumor microenvironment.
